Does One CE Mark Still Cover Europe? A Five-Track Market-Entry Plan
A five-track European medical-device entry playbook: use one CE programme for the EU/EEA core, then treat Great Britain, Switzerland, Russia/EAEU, and Ukraine as distinct regulatory extensions with their own representatives, registrations, and risk gates.
Regional verdict
Europe offers the largest regional leverage in this library because one CE conformity programme opens the EU/EEA core. But Europe is no longer one compliance block: the EU runs MDR/IVDR through national competent authorities and Notified Bodies; Great Britain adds UKRP, MHRA registration, and the long-term UKCA fork while Northern Ireland remains under EU MDR; and Switzerland requires a separate CH-REP, Swiss declaration, and Swissmedic notification after the medical-device MRA froze. Russia/EAEU and Ukraine sit outside that CE core on independent national or regional tracks. The operating model is therefore CE first, low-marginal-cost UK and Swiss extensions second, and separate risk decisions for Russia/EAEU and Ukraine.
Standard pathway flow
Use the EU CE workstream as the technical-documentation spine, but do not mistake document reuse for a single Europe-wide filing.
1. Fix scope, classification, and the target geography
Confirm MDR versus IVDR and the EU risk class first. At the same time, separate the EU/EEA core, Great Britain, Northern Ireland, Switzerland, Russia/EAEU, and Ukraine: each fork changes the representative, filing, language, and maintenance stack.
2. Select the Notified Body and build the CE dossier in parallel
Verify that the Notified Body is designated for the device scope, reserve capacity early, and compile the MDR/IVDR technical documentation, clinical or performance evidence, risk management, QMS, PMS/PMCF, labelling, and declaration materials. The EU page identifies Notified Body capacity as the main bottleneck.
3. Complete conformity assessment and issue the CE package
For devices requiring third-party assessment, complete the Notified Body QMS audit and technical review, close deficiencies, receive the certificate, issue the EU Declaration of Conformity, and affix CE. Eligible Class I devices follow the self-declaration route described on the EU page.
4. Lock the representative and importer system before launch
Non-EU/EEA manufacturers appoint an EU Authorized Representative and keep the importer role distinct. Add a UKRP for Great Britain and a CH-REP for Switzerland; Russia/EAEU requires an EAEU Authorized Representative, while Ukraine requires a Ukrainian Authorized Representative even though certificate title may vary by filing approach.
5. File each extension and maintain local obligations
Register CE- or UKCA-marked devices with MHRA for Great Britain, complete Swissmedic notification or submission with the Swiss declaration and CH-REP, and run the separate Russian/EAEU or Ukrainian dossier where chosen. Maintain local-language labels, importer records, vigilance, certificate updates, and country-specific change filings.
License-holder arrangements
The CE-core structure is the clearest Mode A representative model in this library: the manufacturer retains control while EU AR, UKRP, and CH-REP provide the mandatory local regulatory presence. That is the opposite of the distributor-controlled Mode B pattern documented across much of Southeast Asia. The contrast stops at the CE core: Russia/EAEU is Mode B, and Ukraine remains Mode C because certificate title depends on the filing approach.
EU / Great Britain / Switzerland: Mode A
The manufacturer keeps the registration or filing in its own name and appoints the required representative: EU AR, UKRP, or CH-REP. Keep these regulatory roles separate from the commercial distributor where practical; representative changes still require database, filing, or label updates.
Russia / EAEU: Mode B
An EAEU-registered legal entity must act as Authorized Representative, and the registration certificate is typically issued in that representative’s name. The source page flags sanctions status and representative reliability as direct certificate-control risks.
Ukraine: Mode C
A Ukrainian Authorized Representative is mandatory, but the registration certificate may be issued in either the representative’s or the manufacturer’s name depending on the filing approach. Contract for title and continuity explicitly because wartime interruption can force an immediate variation.
A mandatory local representative does not automatically mean local certificate ownership. EU AR, UKRP, and CH-REP satisfy local regulatory presence while control stays with the manufacturer; Russia/EAEU instead places the certificate with the local Authorized Representative, and Ukraine leaves the title structurally negotiable.
Reference-certificate leverage
- Inside the EU, an FDA, NMPA, or other foreign approval is not a substitute for CE conformity assessment. The EU page states that FDA evidence can support the dossier, but no EU MDR process step is waived and FDA approval is not treated as equivalent to CE.
- The direction reverses once CE is issued: the CE-sequencing handbook describes CE as the world’s most widely leveraged medical-device reference certificate, with formal recognition or evidentiary weight across multiple regions.
- Within this five-track plan, CE has the strongest extension value in Great Britain and Switzerland. Great Britain accepts valid CE during its stated transition window but still requires UKRP and MHRA registration; Switzerland reuses the CE file but, after the MRA freeze, still requires CH-REP, a Swiss declaration, and a separate Swissmedic step. CE is only supporting material in Russia/EAEU and Ukraine, not a replacement for their local tracks.
Suggested entry sequence
Build the MDR/IVDR dossier, reserve the Notified Body, appoint the EU AR where required, and secure CE first. This is the regional leverage asset: the same conformity programme opens the unified core, while national procurement, reimbursement, and language work remains separate.
Reuse the CE package while adding the local representative, registration or notification, declaration, and label steps. The UK page describes the CE transitional route as the lowest-marginal-cost UK path, while the Swiss page describes post-CE registration as a comparatively manageable increment despite the MRA freeze.
Do not treat either as a CE extension. Russia/EAEU requires a separate Russian-language dossier, local certificate holder, and sanctions/export-control review; Ukraine requires its own representative, Ukrainian dossier, and wartime continuity planning. Enter only after the legal, payment, logistics, representative, and continuity gates are acceptable.
Country-by-country delta table
| Country | Regulator | Registration form | Licence holder mode | Validity | Key special requirement |
|---|---|---|---|---|---|
| European Union / EEA | EU MDR / IVDR; national competent authorities; Notified Bodies | CE marking: eligible Class I self-declaration; Notified Body conformity assessment for Class IIa and above and specified Class I aspects | Mode A — manufacturer retains control; non-EU/EEA manufacturer appoints a mandatory EU AR | CE certificate typically 5 years; annual Notified Body surveillance during validity | MDR/IVDR technical file and clinical/performance evidence; Notified Body queue; EUDAMED/UDI; target-state languages |
| United Kingdom | MHRA | Great Britain: mandatory MHRA product registration using accepted CE during the transition or UKCA; Northern Ireland remains on EU MDR with CE / CE UKNI | Mode A — manufacturer retains control and appoints a mandatory UK Responsible Person | UKCA certificate typically 5 years; CE-based access depends on the CE certificate remaining valid through the stated transition window | GB / Northern Ireland split; UKRP on labelling; English; CE acceptance stated through 30 June 2030 while UK reform remains ongoing |
| Switzerland | Swissmedic / MedDO / IvDO | Class I Swissmedic notification; Class IIa/IIb/III submission using a current CE / Notified Body certificate plus a separate Swiss declaration | Mode A — filing runs in the manufacturer’s name; CH-REP is mandatory for manufacturers outside Switzerland | No conventional registration certificate; notification/submission remains valid indefinitely while CE and technical documentation are maintained | MRA freeze removed automatic Swiss coverage; separate CH-REP, Swiss declaration, Swissmedic step, and DE/FR/IT labelling remain required |
| Russia / EAEU | Roszdravnadzor / Eurasian Economic Commission | EAEU conformity assessment where required plus State Registration Certificate (РУ); one member-state registration covers the five EAEU states | Mode B — mandatory EAEU Authorized Representative; the РУ is typically issued in that representative’s name | New registrations typically indefinite; some older certificates have 5-year terms | Certified Russian dossier; local clinical work or site inspection may apply; sanctions, export-control, payment, and holder risks require a separate gate |
| Ukraine | Ministry of Health / State Service on Medicines and Narcotics Control | National State Registration Certificate under the current MDD-based technical regulations; CE documentation supports but does not replace the filing | Mode C — Ukrainian Authorized Representative mandatory; certificate may be in the representative’s or manufacturer’s name depending on filing approach | Typically 5 years | Certified Ukrainian translation and legalization; wartime continuity and review timing remain uncertain; EU MDR alignment timeline is TBD |
Common pitfalls
- Waiting for a finished dossier before contacting a Notified Body: the EU page identifies the Notified Body queue as the main bottleneck and recommends starting outreach in parallel with technical-document preparation.
- Treating legacy MDD certificates as permanently valid or interchangeable with MDR CE: the EU page preserves transition only under stated conditions, with Class III and Class IIb implantables moving by 31 December 2027 and other Class IIb / Class IIa devices by 31 December 2028. PMS, vigilance, and an MDR migration plan still apply during transition.
- Assuming CE automatically completes UK access: Great Britain still requires a UKRP and MHRA registration, the page states CE acceptance only through 30 June 2030, and Northern Ireland remains a separate EU MDR / CE or CE UKNI track.
- Assuming EU approval automatically covers Switzerland: after the medical-device MRA froze, CE remains the technical basis but no longer removes the separate CH-REP, Swiss declaration, Swissmedic notification/submission, and label-update obligations.
- Treating Russia/EAEU or Ukraine as another low-cost CE extension: both retain independent filings, local representatives, language requirements, and country-specific continuity risks; Russia/EAEU also adds the source page’s explicit sanctions and export-control gate.
Explore the country pages
Each row links to the full country regulatory report for registration pathway, timeline, cost, and post-market obligations.